文献速递乳房整形与再造

新辅助化疗对即刻乳房重建术后安全结局的影响

The Effect of Neoadjuvant Chemotherapy on Safety Outcomes Following Immediate Breast Reconstruction.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2022-03-02

该回顾性队列研究纳入2013年1月至2019年5月间接受乳房切除联合即刻乳房重建的乳腺癌患者300例,其中接受新辅助化疗者23例(7.7%),未接受者277例(92%)。两组总体并发症发生率、主要与次要并发症发生率、局部区域复发率、辅助治疗时间及延迟率均相似,但新辅助化疗组总生存率显著低于未接受组(82.6% vs 98.2%,p<0.001)。

要点

  • 新辅助化疗组与未接受组总体并发症发生率相似(37.5% vs 21.7%,p=0.148)。
  • 两组辅助治疗时间(p=0.629)及延迟率(p=0.305)均相似。
  • 新辅助化疗组总生存率显著低于未接受组(82.6% vs 98.2%,p<0.001)。

核心结论

  • 接受与未接受新辅助化疗的即刻乳房重建患者,并发症发生率及辅助治疗时机无差异。
  • 接受新辅助化疗的即刻乳房重建患者总生存率低于未接受者(82.6% vs 98.2%,p<0.001)。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月至2019年5月间接受乳房切除联合即刻乳房重建的乳腺癌患者300例。
  • 共审查1832例患者,最终纳入300例(7.1%);其中未接受新辅助化疗者277例(92%),接受者23例(7.7%)。

主要发现

  • 未接受新辅助化疗组N1和N2肿瘤淋巴结状态显著多于新辅助化疗组(p<0.001)。
  • 总体并发症发生率新辅助化疗组37.5% vs 未接受组21.7%(p=0.148)。
  • 主要并发症发生率新辅助化疗组29.6% vs 未接受组21.7%(p=0.823);次要并发症发生率26.7% vs 8.70%(p=0.0970)。
  • 局部区域复发率(p=1.00)、辅助治疗时间(p=0.629)及延迟率(p=0.305)两组相似。
  • 总生存率新辅助化疗组82.6% vs 未接受组98.2%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mastectomy and immediate breast reconstruction (MIBR) are becoming an increasingly popular option for women with breast cancer. However, MIBR is associated with a higher risk of postoperative complications compared to mastectomy alone, which may delay adjuvant cancer therapy. The main objective of this retrospective cohort study was to investigate oncologic outcomes in MIBR patients with and without neoadjuvant chemotherapy (NACT). METHODS: A 6-year retrospective study of breast cancer patients treated with MIBR was conducted from January 2013 to May 2019. The primary outcome was a delay in adjuvant radiochemotherapy. Secondary outcomes included postoperative complications and locoregional recurrences. RESULTS: Of 1832 patients reviewed, 300 (7.1%) were included. The cohort consisted of 277 (92%) MIBR patients without NACT and 23 (7.7%) with NACT. There was significantly more N1 and N2 tumor node status in the non-NACT group compared to the NACT group (p<0.001). The overall complication rates were similar in the NACT group compared to non-NACT (37.5% versus 21.7%, p=0.148). The rates of major and minor complications were also similar between NACT and non-NACT groups (Major: 29.6% versus 21.7%, p=0.823) and (Minor: 26.7% versus 8.70%, p =0.0970). The rates of locoregional recurrence (p=1.00), time to adjuvant therapy (p=0.629), and rates of delay (p=0.305) was also similar between groups. Overall survival was significantly lower in the NACT group compared to non-NACT (98.2% versus 82.6%, p<0.001). CONCLUSIONS: There was no difference in complication rates, or timing to adjuvant therapy, among MIBR patients with and without NACT. However, MIBR patients who received NACT had worse overall survival than MIBR patients without NACT.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Grigor EJM, Stein MJ, Arnaout A, et al. The Effect of Neoadjuvant Chemotherapy on Safety Outcomes Following Immediate Breast Reconstruction. J Plast Reconstr Aesthet Surg. 2022. PMID: 35396192. doi:10.1016/j.bjps.2022.02.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。